rss
Thorax 61:491-495 doi:10.1136/thx.2004.039164
  • Sleep disordered breathing

Treatment of obstructive sleep apnoea leads to improved microvascular endothelial function in the systemic circulation

  1. J L Lattimore1,2,
  2. I Wilcox1,2,
  3. M Skilton1,2,
  4. M Langenfeld1,2,
  5. D S Celermajer1,2
  1. 1Department of Cardiology, Royal Prince Alfred Hospital Sydney, NSW, Australia
  2. 2Department of Medicine, University of Sydney, NSW, Australia
  1. Correspondence to:
    Dr J L Lattimore
    Department of Cardiology, Royal Prince Alfred Hospital, Missenden Road, Camperdown, NSW 2050, Sydney, Australia; jodee.lattimore{at}email.cs.nsw.gov.au
  • Received 13 December 2004
  • Accepted 17 January 2006
  • Published Online First 14 March 2006

Abstract

Background: Obstructive sleep apnoea (OSA) is a common and potentially reversible cause of systemic hypertension. The mechanisms whereby OSA leads to hypertension and the effects of treatment on arterial function, however, are not well established. Microvascular arterial endothelial and smooth muscle function was assessed in subjects with OSA before and after treatment with continuous positive airways pressure (CPAP).

Methods: Ten subjects of mean (SE) age 49 (8) years with at least moderately severe OSA had detailed forearm vascular reactivity studies before and after 3 months of CPAP treatment. The systemic circulation was assessed by measuring brachial artery pressure, flow and resistance responses to intra-arterial infusions of acetylcholine (ACh; an endothelium dependent vasodilator), sodium nitroprusside (SNP; an endothelium independent vasodilator), l-NMMA (a nitric oxide (NO) antagonist), and l-arginine (the substrate for NO).

Results: Before CPAP, ACh and SNP infusions increased forearm blood flow in a dose dependent manner (p<0.01). After CPAP, endothelium dependent dilation to ACh was significantly increased (434 (23)% of baseline after CPAP v 278 (20)% before CPAP, p<0.001), whereas SNP induced dilation was unchanged. Resting NO production was higher after CPAP, evidenced by a significantly greater reduction in basal flow by l-NMMA (p = 0.05). l-Arginine reversed the effect of l-NMMA in all cases.

Conclusion: In patients with OSA, treatment with CPAP improves baseline endothelial NO release and stimulates endothelium dependent vasorelaxation in the systemic circulation. This is a potential mechanism for improving systemic and vascular function in patients with OSA treated with CPAP.

Footnotes

  • Published Online First 14 March 2006

  • Dr Lattimore is supported by a Cardiac Society of Australia and New Zealand Research Scholarship. This work was supported in part by a grant-in-aid from the National Heart Foundation of Australia.

  • A/Prof Ian Wilcox is a minor shareholder in ResMed, Australia.